Latest Ratios: P/E Ratio -0.4x · EV/EBITDA N/A · ROE -45.1%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1M | $3M | $8M | $4M | $6M | $22M | $25M | $35M | $12M | $12M | $41M |
| Enterprise Value | $855223 | $2M | $4M | $-1639397 | $-12129623 | $-3259176 | $21M | $29M | $-58512 | $3M | $64M |
| P/E Ratio → | -0.42 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.23 | 0.56 | 1.60 | 0.87 | 0.88 | 3.26 | 3.14 | 29.83 | 8.16 | 2.95 | 12.80 |
| P/B Ratio | 0.24 | 0.65 | 1.30 | 0.30 | 0.31 | 0.71 | 0.88 | 4.19 | 0.93 | 1.48 | 1.84 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.50 | 0.79 | -0.37 | -1.64 | -0.48 | 2.55 | 24.54 | -0.04 | 0.68 | 20.05 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 36.2% | 36.2% | 41.3% | 51.2% | 17.8% | -28.4% | 35.3% | 24.3% | 54.8% | 93.0% | 71.9% |
| Operating Margin | -205.7% | -205.7% | -72.3% | -137.0% | -188.8% | -524.0% | -159.0% | -1657.9% | -1152.3% | -355.6% | -584.1% |
| Net Profit Margin | -48.1% | -48.1% | -139.5% | -313.9% | -207.3% | -216.2% | -57.9% | -2464.1% | -920.8% | -390.1% | -615.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -45.1% | -45.1% | -74.4% | -83.2% | -59.0% | -49.1% | -25.2% | -272.5% | -129.5% | -104.0% | -62.9% |
| ROA | -23.3% | -23.3% | -42.4% | -57.5% | -42.2% | -32.1% | -11.6% | -101.8% | -66.4% | -42.9% | -30.0% |
| ROIC | -249.2% | -249.2% | -58.7% | -96.7% | -260.1% | -179.6% | -73.7% | -980.5% | -1548.7% | -48.6% | -32.3% |
| ROCE | -129.5% | -129.5% | -27.0% | -29.9% | -44.1% | -88.9% | -37.6% | -81.0% | -99.2% | -43.1% | -30.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.02 | 0.08 | 0.10 | 0.11 | 0.33 | 0.27 | — | — | 1.13 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.06 | -0.66 | -0.43 | -0.89 | -0.81 | -0.16 | -0.74 | -0.94 | -1.14 | 1.04 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -1437.75 | -129.85 | -5773.20 | -5.27 | -19.99 | -13.86 |
Net cash position: cash ($259000) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.09 | 3.09 | 3.61 | 4.17 | 6.03 | 7.02 | 5.02 | 4.98 | 7.49 | 4.27 | 16.69 |
| Quick Ratio | 2.50 | 2.50 | 3.25 | 3.63 | 5.48 | 6.14 | 4.42 | 4.67 | 7.43 | 4.20 | 16.61 |
| Cash Ratio | 2.22 | 2.22 | 1.66 | 3.24 | 4.90 | 5.69 | 4.07 | 4.44 | 7.15 | 3.69 | 16.16 |
| Asset Turnover | — | 0.74 | 0.37 | 0.23 | 0.26 | 0.15 | 0.17 | 0.04 | 0.06 | 0.24 | 0.06 |
| Inventory Turnover | 2.56 | 2.56 | 3.28 | 1.11 | 2.63 | 1.96 | 1.36 | 0.49 | 3.65 | 1.24 | 3.55 |
| Days Sales Outstanding | — | 31.93 | 85.01 | 42.12 | 60.08 | 73.75 | 63.88 | 187.96 | 41.89 | 111.97 | 61.02 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $1M | $1M | $1M | $599389 | $532015 | $248975 | $159077 | $94160 | $53905 | $55458 |
Imminent liquidity exhaustion
According to recent market data, RKDA trades at a P/S multiple of 0.22, which, as noted in financial filings, suggests the market is pricing the firm as a distressed asset rather than a viable growth-stage biotech entity with a sustainable long-term intellectual property licensing model.
The extremely low P/S ratio indicates that investors have largely abandoned growth expectations, focusing instead on the company's terminal value in a potential liquidation scenario. This valuation level implies that the market views the current patent portfolio as having minimal commercial utility outside of a distressed sale to a larger industry player.
Based on reported figures, RKDA's ROIC has remained consistently negative, reaching -20.1% in 2026Q1, which demonstrates that the company is failing to generate any meaningful return on its invested capital while struggling to transition toward a capital-light licensing framework within the agricultural inputs sector.
The persistent negative ROIC highlights a fundamental inability to deploy capital effectively, as the costs associated with maintaining R&D and corporate infrastructure continue to outpace the revenue generated by its proprietary wheat traits. This trend suggests that the company's historical capital allocation has been value-destructive, necessitating a radical shift in operational focus to prevent further erosion of shareholder equity.
As reported in financial statements, RKDA's asset turnover ratio remains critically low at 0.19 in 2026Q1, reflecting a structural inability to leverage its asset base effectively as the firm pivots away from consumer-packaged goods toward a more volatile, project-based intellectual property licensing model.
The high inventory days and inconsistent cash conversion cycle suggest that the company is still burdened by the remnants of its previous business model, which complicates the transition to a leaner licensing structure. Investors should monitor whether the company can successfully rationalize its working capital requirements, as the current inefficiency places additional strain on an already depleted cash position.
According to recent SEC filings, RKDA's cash and equivalents have dwindled to a precarious $259,000, a level that warrants significant concern regarding the firm's ability to sustain operations without immediate external financing or a rapid, successful monetization of its remaining intellectual property assets.
While the current ratio of 3.79 might appear superficially healthy, it is heavily skewed by the lack of significant current liabilities rather than an abundance of liquid assets. This liquidity position is highly vulnerable to even minor operational shocks, suggesting that the company may be forced into dilutive financing or strategic asset sales in the very near term.
The P/B ratio of 0.23 is frequently misapplied by investors to suggest that RKDA is undervalued, yet this metric fails to account for the rapid erosion of tangible assets and the high probability that the company's book value is significantly overstated relative to its liquidation potential.
Using the P/B ratio in this context is misleading because it ignores the fact that the company's primary assets are intangible and likely impaired, given the history of failed strategic pivots. A more appropriate focus for this business model would be the cash burn rate relative to the remaining runway, as the book value provides no insight into the firm's ability to survive as a going concern.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RKDA stock.
Arcadia Biosciences, Inc.'s current P/E ratio is -0.4x. This places it at the 50th percentile of its historical range.
Arcadia Biosciences, Inc.'s return on equity (ROE) is -45.1%. The historical average is -90.8%.
Based on historical data, Arcadia Biosciences, Inc. is trading at a P/E of -0.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Arcadia Biosciences, Inc. has 36.2% gross margin and -205.7% operating margin.